Arbutin attenuates behavioral impairment and oxidative stress in an animal model of Parkinson's disease

Document Type : Original Research Article


1 Student Research Committee, Babol University of Medical Sciences, Babol, Iran

2 Department of Clinical Biochemistry, Faculty of Medicine, Babol University of Medical Sciences, Babol, Iran

3 Cellular and Molecular Biology Research Center, Health Research Institute, Babol University of Medical Sciences, Babol, Iran

4 Neuroscience Research Center, Health Research Institute, Babol University of Medical Sciences, Babol, Iran

5 Department of Physiology, Faculty of Medicine, Babol University of Medical Sciences, Babol, Iran

6 Department of Pharmacology, Faculty of Medicine, Babol University of Medical Sciences, Babol, Iran

7 Department of Biostatistics and Epidemiology, Babol University of Medical Sciences, Babol, Iran

8 Department of Anatomy, Embryology and Histology, Faculty of Medicine, Babol University of Medical Sciences, Babol, Iran


Objective: Arbutin has been shown to have antioxidant and free-radical scavenging properties. The aim of this study was to investigate the effects of arbutin administration on behavioral impairment, and oxidative and nitrosative stress in a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine(MPTP)-induced animal model of Parkinson’s disease (PD).
Materials and Methods: PD model was developed by 4 intraperitoneal (i.p.) injections of MPTP (20 mg/kg) with 2 h intervals in mice. Experimental groups received once daily injection of saline as vehicle (control group) or arbutin (50 mg/kg, i.p.) one week before MPTP injections and this protocol was continued seven days post lesion. Behavioral deficits were evaluated using locomotion test, hanging wire test and forepaw stride length. Parameters indicating the oxidation levels including lipid peroxidation marker (TBARS), nitrite, protein carbonyl levels and antioxidant activity including ferric reducing antioxidant power (FRAP) were assessed in serum and midbrain samples.
Results: Treatment with arbutin improved motor functions in an MPTP-induced PD model compared to control group (p<0.001). Mice treated with MPTP showed reduced levels of FRAP (p<0.001) and increased levels of TBARS (p<0.001), nitrite (p<0.001) and protein carbonyl (p<0.01), compared to the control group. In contrast to the MPTP group, arbutin treatment decreased the levels of TBARS (p<0.05), nitrite (p<0.05), protein carbonyl (p<0.05), and increased FRAP levels (p<0.05) in mice with PD.
Conclusion: These findings suggest that arbutin attenuates the behavioral impairment and oxidative stress in a PD animal model.


Main Subjects

Benzie IF, Strain JJ. 1996. The ferric reducing ability of plasma (FRAP) as a measure of “antioxidant power”: the FRAP assay. Anal Biochem, 239: 70-76.
Berlett BS, Stadtman ER. 1997. Protein oxidation in aging, disease, and oxidative stress. J Biol Chem, 272: 20313-20316.
Betarbet R, Sherer TB, Greenamyre JT. 2002. Animal models of Parkinson's disease. Bioessays,  24: 308-318.
Carmen P, Vlase L, Tamas M. 2009. Natural resources containing arbutin. Determination of arbutin in the leaves of Bergenia crassifolia (L.) Fritsch. acclimated in Romania. Not Bot Horti Agrobo Cluj-Napoca,  37: 129-132.
Dalle-Donne I, Giustarini D, Colombo R, Rossi R, Milzani A. 2003. Protein carbonylation model of Parkinson's disease. J Bioenerg Biomembr, 36: 375-379.
Dawson TM, Ko HS, Dawson VL. 2010. Genetic animal models of Parkinson's disease. Neuron,  66: 646-661.
Eriksen JL, Petrucelli L. 2004. Parkinson's disease–molecular mechanisms of disease. Drug Discov Today Dis Mech, 1:399-405.
Dawson TM, Ko HS, Dawson VL. 2010. Genetic animal models of Parkinson's disease. Neuron,  66: 646-661.
Essawy SS, Tawfik MK, Korayem HE. 2017. Effects of adenosine receptor antagonists in MPTP mouse model of Parkinson’s disease: mitochondrial DNA integrity. Arch Med Sci,  13: 659-669.
Gerlach M, Riederer P, Przuntek H, Youdim MB. 1991. MPTP mechanisms of neurotoxicity and their implications for Parkinson's disease. Eur J Pharmacol Mol Pharmacol, 208: 273-286.
Giasson BI, Ischiropoulos H, Lee VM-Y, Trojanowski JQ. 2002. The relationship between oxidative/nitrative stress and pathological inclusions in Alzheimer’s and Parkinson’s diseases1, 2 1 2. Free Radic Biol Med,  32: 1264-1275.
He X-J, Uchida K, Megumi C, Tsuge N, Nakayama H. 2015. Dietary curcumin supplementation attenuates 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine (MPTP) neurotoxicity in C57BL mice. J Toxicol Pathol, 28: 197-206.
Ju MS, Kim HG, Choi JG, Ryu JH, Hur J, Kim YJ, Oh MS. 2010a. Cassiae semen, a seed of Cassia obtusifolia, has neuroprotective effects in Parkinson’s disease models. Food Chem Toxicol, 48: 2037-2044.
Ju MS, Lee P, Kim HG, Lee KY, Hur J, Cho S-H, Sung SH, Oh MS. 2010b. Protective effects of standardized Thuja orientalis leaves against 6-hydroxydopamine-induced neurotoxicity in SH-SY5Y cells. Toxicol in Vitro, 24: 759-765.
Khadir F, Pouramir M, Joorsaraee SG, Feizi F, Sorkhi H, Yousefi F. 2015. The effect of arbutin on lipid peroxidation and antioxidant capacity in the serum of cyclosporine-treated rats. Casp J Int Med, 6: 196-200.
Khanjarsim V, Karimi J, Khodadadi I, Mohammadalipour A, Goodarzi MT, Solgi G, Hashemnia M. 2017. Ameliorative Effects of Nilotinib on CCl4 Induced Liver Fibrosis Via Attenuation of RAGE/HMGB1 Gene Expression and Oxidative Stress in Rat. Chonnam Med J, 53: 118-126.
Koppula S, Kumar H, More SV, Lim H-W, Hong S-M, Choi D-K. 2012. Recent updates in redox regulation and free radical scavenging effects by herbal products in experimental models of Parkinson’s disease. Molecules,  17: 11391-11420.
Langston JW, Irwin I, Langston EB, Forno LS. 1984. 1-Methyl-4-phenylpyridinium ion (MPP+): identification of a metabolite of MPTP, a toxin selective to the substantia nigra. Neurosci Lett, 48: 87-92.
Lee C-H, Hwang D-S, Kim HG, Oh H, Park H, Cho JH, Lee JM, Jang JB, Lee KS, Oh MS. 2010. Protective effect of Cyperi rhizoma against 6-hydroxydopamine-induced neuronal damage. J Med Food,  13: 564-571.
Lee H-J, Kim K-W. 2012. Anti-inflammatory effects of arbutin in lipopolysaccharide-stimulated BV2 microglial cells. Inflamm Res, 61: 817-825.
Levy OA, Malagelada C, Greene LA. 2009. Cell death pathways in Parkinson’s disease: proximal triggers, distal effectors, and final steps. Apoptosis,  14: 478-500.
Liberatore GT, Jackson-Lewis V, Vukosavic S, Mandir AS, Vila M, McAuliffe WG, Dawson VL, Dawson TM, Przedborski S.. 1999. Inducible nitric oxide synthase stimulates dopaminergic neurodegeneration in the MPTP model of Parkinson disease. Nat Med,  5: 1403-1409.
Lin MT, Beal MF. 2006. Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases. Nature,  443: 787-795.
Lu K-T, Ko M-C, Chen B-Y, Huang J-C, Hsieh C-W, Lee M-C, Chiou RY, Wung BS, Peng CH, Yang YL. 2008. Neuroprotective effects of resveratrol on MPTP-induced neuron loss mediated by free radical scavenging. JAgric Food Chem, 56: 6910-6913.
Luo F-C, Wang S-D, Qi L, Song J-Y, Lv T, Bai J. 2011. Protective effect of panaxatriol saponins extracted from Panax notoginseng against MPTP-induced neurotoxicity in vivo. J Ethnopharmacol, 133: 448-453.
Mandel S, Youdim MB. 2004. Catechin polyphenols: neurodegeneration and neuroprotection in neurodegenerative diseases. Free Radic Biol Med, 37: 304-317.
Marzatico F, Café C, Taborelli M, Benzi G. 1993. Experimental Parkinson's disease in monkeys. Effect of ergot alkaloid derivative on lipid peroxidation in different brain areas. Neuroch Res,  18: 1101-1106.
Mena MA, Casarejos MJ, Canals S. 2005. Nitric oxide and dopamine neurons. Implications for Parkinson's disease. Current Med Chem Cent Nerv Sys Agents,  5: 193-205.
Mohanasundari M, Srinivasan M, Sethupathy S, Sabesan M. 2006. Enhanced neuroprotective effect by combination of bromocriptine and Hypericum perforatum extract against MPTP-induced neurotoxicity in mice. J Neurol Sci, 249: 140-144.
Moreira EL, Rial D, Duarte FS, De Carvalho CR, Horst H, Pizzolatti MG, Prediger RDS, Ribeiro-do-Valle RM. 2010. Central nervous system activity of the proanthocyanidin‐rich fraction obtained from Croton celtidifolius in rats. J Pharm Pharmacol, 62:1061-1068.
Myagmar B-E, Shinno E, Ichiba T, Aniya Y. 2004. Antioxidant activity of medicinal herb Rhodococcum vitis-idaea on galactosamine-induced liver injury in rats. Phytomedicine,  11: 416-423.
Petkou D, Diamantidis G, Vasilakakis M. 2002. Arbutin oxidation by pear (Pyrus communis L.) peroxidases. Plant Sci, 162: 115-119.
Przedborski S, Tieu K, Perier C, Vila M. 2004. MPTP as a mitochondrial neurotoxic model of Parkinson's disease. J Bioenerg Biomembr, 36: 375-379.
Przedborski S, Vila M. 2001. MPTP: a review of its mechanisms of neurotoxicity. Clinical Neurosci Res, 1: 407-418.
RajaSankar S, Manivasagam T, Sankar V, Prakash S, Muthusamy R, Krishnamurti A, Surendran S. 2009. Withania somnifera root extract improves catecholamines and physiological abnormalities seen in a Parkinson's disease model mouse. Journal of Ethnopharmacol,  125: 369-373.
Rajeswari A. 2006. Curcumin protects mouse brain from oxidative stress caused by 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydro pyridine. Eur Rev Med Pharmacol Sci, 10: 157-161.
Sankar SR, Manivasagam T, Krishnamurti A, Ramanathan M. 2007. The neuroprotective effect of Withania somnifera root extract in MPTP-intoxicated mice: An analysis of behavioral and biochemical varibles. Cell  Mol Biol Lett,  12:473-481.
Shahaboddin M-E, Pouramir M, Moghadamnia A-A, Parsian H, Lakzaei M, Mir H. 2011. Pyrus biossieriana Buhse leaf extract: An antioxidant, antihyperglycaemic and antihyperlipidemic agent. Food Chem,  126: 1730-1733.
Sharma A, Kaur P, Kumar B, Prabhakar S, Gill K. 2008. Plasma lipid peroxidation and antioxidant status of Parkinson's disease patients in the Indian population. Parkinsonism  Relat Dis, 14: 52-57.
Singh N, Pillay V, Choonara YE. 2007. Advances in the treatment of Parkinson's disease. Prog Neurobiol, 81: 29-44.
Suchowersky O. 2002. Parkinson’s disease: medical treatment of moderate to advanced disease. Curr Neurol Neurosci Rep, 2: 310-316.
Tillerson JL, Caudle WM, Reverón ME, Miller GW. 2002. Detection of behavioral impairments correlated to neurochemical deficits in mice treated with moderate doses of 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine. Exp Neurol,  178: 80-90.
Wakamatsu M, Ishii A, Iwata S, Sakagami J, Ukai Y, Ono M, Kanbe D, Muramatsu S, Kobayashi K, Iwatsubo T, Yoshimoto M. 2008. Selective loss of nigral dopamine neurons induced by overexpression of truncated human α-synuclein in mice. Neurobi Aging,  29: 574-585.
Yousefi F, Mahjoub S, Pouramir M, Khadir F. 2013. Hypoglycemic activity of Pyrus biossieriana Buhse leaf extract and arbutin: Inhibitory effects on alpha amylase and alpha glucosidase. Casp J Int Med,  4: 763-767.